Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMASTer: LITT for Recurrent Brain Metastases After SRS
NCT05124912Recruiting
- Sponsor
- Monteris Medical
- Start
- May 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in brain metastases and radiation necrosis (RN) (2 arms), sponsored by Monteris Medical. Primary endpoints: Progression-Free Survival at 24 months and Time to Steroid Freedom at 3 months. Started May 2022; status: recruiting.
02
Conditions
brain metastasesradiation necrosis (RN)
Beyond the preview
Go deeper on NCT05124912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124912.